Centenial Surgical Suture Ltd

Centenial Surgical Suture Ltd., a micro-cap surgical sutures manufacturer with a market capitalisation of ₹33.00 crores, reported a concerning quarter ended March 2026, with net losses widening to ₹2.31 crores compared to a loss of ₹1.18 crores in the year-ago period. The quarter marked the company's weakest operational performance in recent years, with revenue declining 15.34% sequentially to ₹12.58 crores whilst operating margins compressed to just 7.39%—the lowest in the trailing twelve-month period.

Centenial Surgical Suture Ltd has reported a significant downturn in its financial performance for the quarter ended March 2026, marking a stark reversal from its previously positive trajectory. The company’s key metrics, including net sales, profit after tax, and operating margins, have all deteriorated sharply, signalling mounting challenges in the healthcare services sector for this micro-cap player.

Centenial Surgical Suture Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Centenial Surgical Suture Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Centenial Surgical Suture Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Centenial Surgical Suture Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

For the fifth consecutive trading session, Centenial Surgical Suture Ltd has closed lower, slipping to a fresh 52-week low of Rs 76.27 on 30 Mar 2026. This marks a 12.32% decline over the past five days, extending a downward trend that has seen the stock underperform the broader market significantly.

For the fourth consecutive session, Centenial Surgical Suture Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 77 on 27 Mar 2026. This marks a significant 59.2% drop from its 52-week high of Rs 189, underscoring persistent selling pressure despite pockets of operational improvement.

Centenial Surgical Suture Ltd’s stock price declined to a fresh 52-week low of Rs.77.3 on 25 March 2026, marking a significant downturn amid broader market gains. The stock underperformed its sector and has been on a downward trajectory over the past three days, reflecting ongoing concerns about its financial performance and valuation metrics.

Despite a broadly positive market environment, Centenial Surgical Suture Ltd has fallen sharply to a new 52-week low of Rs 80.28 on 24 Mar 2026, marking a significant divergence from sector gains and broader indices.

Centenial Surgical Suture Ltd’s stock price declined to a fresh 52-week low of Rs.82.66 on 23 March 2026, reflecting ongoing pressures within the healthcare services sector and broader market weakness. The stock’s performance continues to trail key benchmarks amid subdued financial metrics and challenging market conditions.

Centenial Surgical Suture Ltd has demonstrated a notable turnaround in its financial performance for the quarter ended December 2025, shifting from a flat to a positive growth trajectory. Despite lingering challenges in return metrics, the company’s latest quarterly results reveal encouraging signs of revenue expansion and profitability improvements, positioning it cautiously ahead in the competitive healthcare services sector.

Centenial Surgical Suture Ltd., a micro-cap surgical suture manufacturer with a market capitalisation of ₹36.00 crores, reported a return to profitability in Q3 FY26 with net profit of ₹0.15 crores, a sharp reversal from the ₹0.85 crores loss recorded in the corresponding quarter last year. However, the stock's 3.06% gain to ₹101.00 on February 13, 2026, following the results, belies deeper structural challenges that continue to plague the company's financial health and long-term growth prospects.

Centenial Surgical Suture Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 12 Feb 2026, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The healthcare services company’s Mojo Score improved to 31.0, reflecting a modest recovery in market sentiment, though its financial and valuation metrics continue to signal caution for investors.